Home Contact
Login   |  Tell a Friend
Financial Optimization through Technology Innovation
mutual fund
 Top Fund Managers
Latest Mutual Fund News Latest Mutual Fund News

Financial Advisor Sponsor:Dean L. Boebinger


 Bookmark this site!
Follow FundMojo on Twitter
Get Fund Information

Get Stock News

(Enter Stock Symbol)

Partner Sites

Annuities
Wall Street Journal
eHealthInsurance
Fund Mojo on Facebook
Fund Mojo help you discover the best fund managers, funds, and related information

Fund Intelligence | Best Managers | RYOAX Insights | RYOAX Score | RYOAX Performance | RYOAX Manager | RYOAX News | RYOAX Allocation | RYOAX Holdings Change

Mutual Fund Insights: Rydex Biotechnology Adv Fund (RYOAX)

In-depth Analysis of Rydex Biotechnology Adv Fund (RYOAX)

Mutual fund chart: Rydex Biotechnology Adv Fund (RYOAX)

3 months
6 months
1 year
3 year
5 year

See Rydex Biotechnology Adv Fund (RYOAX) performance details as of January 31, 2010

  

    Last Trade: $26.18 on 3/18/2010, Change: +0.05 (0.19%)

  

Fund Manager - Michael P. Byrum

Fund Manager Tenure: 12.0 years   [Similar Funds: RYOIX ]
Fundmojo Fund Grade: B (Score: 0.69)     (What does this score mean?)
Byrum is president and CIO of Rydex Investments, his employer since its foundation in 1993. He has ultimate responsibility for the management of the funds. He was named the president of Rydex Investments in 2004 and has served as chief investment officer since 2003.Prior to joining Rydex Investments, Mr. Byrum worked for Money Management Associates, the investment adviser for Rushmore Funds, Inc. Byrum holds the Charted Financial Analyst designation.  Get more insights on Michael P. Byrum

  

What we like about Rydex Biotechnology Adv Fund (RYOAX) What we like about Rydex Biotechnology Adv Fund (RYOAX)

Data for Rydex Biotechnology Adv Fund (RYOAX) as of January 31, 2010

  • Rydex Biotechnology Adv Fund (RYOAX) management has been with Rydex Biotechnology Adv Fund for 12.0 years
  • Rydex Biotechnology Adv Fund (RYOAX) has good short-term performance (1-year return 24.43% vs 24.07% Health category average)
  • Rydex Biotechnology Adv Fund (RYOAX) has good mid-term performance (3-year return 3.70% vs -0.24% Health category average)
  • Rydex Biotechnology Adv Fund (RYOAX) has good Long-term performance (5-year return 5.51% vs 4.22% Health category average)
  • Rydex Biotechnology Adv Fund (RYOAX) has a lower management fee than its Health average: 1.88% vs 1.91%

  

What we are cautious about Rydex Biotechnology Adv Fund (RYOAX) What we are cautious about Rydex Biotechnology Adv Fund (RYOAX)

Data for Rydex Biotechnology Adv Fund (RYOAX) as of January 31, 2010

  • Rydex Biotechnology Adv Fund is a focused fund with 67.00% of the portfolio on top 10 securities. This tends to produce more volatility compared to a diversified fund. See fund top 10 holdings.
  • Rydex Biotechnology Adv Fund (RYOAX) ratio of up-years vs down years can be improved
  • Rydex Biotechnology Adv Fund (RYOAX) has a Morningstar rating of 3 and below
  • Rydex Biotechnology Adv Fund (RYOAX) is more volatile than its peers as it has a 3-year Standard Deviation of 23.51 that is higher than category average of 18.84
  • Even though Rydex Biotechnology Adv Fund carries no load, it does have a 0.25% of 12b1 promotion, distributions, marketing expenses
See Rydex Biotechnology Adv Fund (RYOAX) performance details as of January 31, 2010

  

  

Interested in other top mutual funds in similar Health category?

Below are some additional Health mutual funds generated out of our database

  

Rydex Biotechnology Adv Fund (RYOAX) Net Asset

Track net asset change of Rydex Biotechnology Adv fund (RYOAX)

DateNet Asset
01/2010$7.53M
11/2009$4.47M
10/2009$5.26M
More historic net asset information on Rydex Biotechnology Adv Fund (RYOAX)

  

Rydex Biotechnology Adv Fund (RYOAX) Portfolio Allocation

Track portfolio allocation change of Rydex Biotechnology Adv fund (RYOAX)

DateCashStockBondOther
11/20090.77%99.23%0%0%
09/20090.22%99.78%0%0%
08/20090.48%99.52%0%0%
Click here to see more historic asset allocation information on Rydex Biotechnology Adv Fund (RYOAX)

  

Most Recent Top 10 Holdings in Rydex Biotechnology Adv Fund (RYOAX)

Discover what Rydex Biotechnology Adv Fund (RYOAX) manager is buying

30-Nov-09
Amgen Inc. [13.1%]
Gilead Sciences, Inc. [11.46%]
Celgene Corporation [8.94%]
Biogen Idec Inc [6.43%]
Genzyme Corporation [6.33%]
Human Genome Sciences, Inc. [5.38%]
Vertex Pharmaceuticals Incorpor [5.29%]
Cephalon, Inc. [4.68%]
Dendreon Corporation [3.77%]
Alexion Pharmaceuticals, Inc. [3.16%]

30-Sep-09
Amgen Inc. [9.99%]
Gilead Sciences, Inc. [8.05%]
Celgene Corporation [6.95%]
Genzyme Corporation [5.05%]
Biogen Idec Inc [4.99%]
Vertex Pharmaceuticals Incorpor [3.43%]
Cephalon, Inc. [2.72%]
Alexion Pharmaceuticals, Inc. [2.58%]
Human Genome Sciences, Inc. [2.47%]
Dendreon Corporation [2.46%]

31-Aug-09
Amgen Inc. [9.78%]
Gilead Sciences, Inc. [7.69%]
Celgene Corporation [6.4%]
Genzyme Corporation [4.9%]
Biogen Idec Inc [4.89%]
Vertex Pharmaceuticals Incorpor [3.34%]
Cephalon, Inc. [2.62%]
Alexion Pharmaceuticals, Inc. [2.58%]
Human Genome Sciences, Inc. [2.56%]
[2.46%]
Click here for Stock Holding Change Map in Rydex Biotechnology Adv Fund (RYOAX)

  

Related books and products to Rydex Biotechnology Adv Fund (RYOAX)

  

Latest News on Rydex Biotechnology Adv (RYOAX)

See what is happening with Rydex Biotechnology Adv Fund (RYOAX)

 

Books and Resources

 

 

See more information on Rydex Biotechnology Adv Fund (RYOAX)